Cardiac arrest patients may be more likely to survive and avoid permanent disabilities when bystanders use a defibrillator to treat them before an ambulance arrives, a new study suggests.
Wilson’s disease patients had been champing at the bit for Teva’s generic version of Syprine that the company called a “lower-cost generic.” But after the drug launched in February 2018, patients discovered that Teva’s generic is not eally that much cheaper than Valeant Pharmaceuticals International’s branded drug.
Shares of ObsEva climbed after the company highlighted a data point from a late-stage trial that showed its fertility treatment nolasiban was successful in improving the pregnancy rate of some women following in vitro fertilization.
Eli Lilly published results from a new Phase IIIb study of Trulicity (dulaglutide) in combination with a SGLT-2 inhibitor showing improved blood sugar control in adults with type 2 diabetes.
ARCA biopharma, based in Westminster, Colorado, announced results from its Phase IIb clinical trial of Gencaro (bucindolol hydrochloride) in patients with atrial fibrillation.
A U.S. administrative court said it has the authority to decide the validity of patents Allergan transferred to a Native American tribe.
Mobile data will be used in Ghana to track and control epidemics, helping prevent a repeat of the 2014 West Africa Ebola outbreak, in a pioneering program announced by Vodafone Foundation.
KemPharm Inc. said the U.S. Food and Drug Administration approved the drugmaker’s opioid painkiller Apadaz for the short-term management of acute pain.
Teva Pharmaceuticals Inc. made more cuts in the United States, this time to real estate holdings. To save money, the company will close its offices in Washington, D.C. and New York City. No jobs were reported to be lost from the cuts.
The passing of tax reform led most analysts to predict that 2018 will be a strong year for mergers and acquisitions. Yet, despite what appears like a good start to the year, not all companies are jumping immediately on the M&A bandwagon.
Pfizer Inc. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted positive opinions recommending that two Pfizer hematology medicines be granted marketing authorizations in the European Union.
A European Medicines Agency panel recommended against approving Puma Biotechnology’s lead breast cancer drug, an outcome the U.S drugmaker signaled in January 2018.
AstraZeneca and Merck announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending a marketing authorization of Lynparza (olaparib) tablets (300 mg twice daily) for use as a maintenance therapy for patients with platinum-sensitive relapsed high grade, epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete response or partial response to platinum-based chemotherapy.
Shire plc announced the U.S. Food and Drug Administration accepted the Biologics License Application and granted priority review for lanadelumab (SHP643).
Beacon Healthcare Communications named Amy Whitcomb as Director of Multi-Channel Marketing in response to growing client needs for integrated multi-channel marketing solutions to drive brand campaign performance.
Compared to inactive people, recreational soccer players have lower cholesterol, blood pressure and resting heart rates as well as less fat mass, a research review suggests.
Novartis is eying a possible 2019 launch for RTH258 (brolucizumab), an ophthalmology drug for the treatment of neovascular age-related macular degeneration. The Swiss-based company is planning to seek regulatory approval of the drug during 2018.
Shares of Regeneron Pharmaceuticals fell slightly in after-hours trading Wednesday following reports by providing doctors of increased observations of known side effects from the blockbuster drug Eylea.
Kite Pharma, a Gilead company, inked a worldwide collaboration deal with Sangamo Therapeutics to develop oncology therapeutics.
Five months after Janssen ended a multi-billion dollar development deal with Achillion Pharmaceuticals for the hepatitis C treatment combination JNJ-4178, the Connecticut-based company is slashing staff and initiating an operational restructuring plan.